E.g., 06/10/2021
E.g., 06/10/2021

bioMérieux announces CE-marking of the new MALDI-TOF mass spectrometry identification system: VITEK® MS PRIME

30 April, 2021

bioMérieux, a world leader in the field of in vitro diagnostics, has announced the CE-marking of VITEK® MS PRIME, the next generation of the VITEK® MS MALDI-TOF1 mass spectrometry system for routine microbial identification in minutes.

bioMérieux – First-Quarter 2021 Business Review

27 April, 2021

bioMérieux, a world leader in the field of in vitro diagnostics, today releases its business review for the three months ended March 31, 2021.

BIOFIRE® Respiratory 2.1 (RP2.1) Panel with SARS-CoV-2 obtains De Novo FDA Authorization

18 March, 2021

Marcy l’Étoile (France) – bioMérieux, a world leader in the field of in vitro diagnostics, today announced that BioFire Diagnostics, its subsidiary specialized in molecular syndromic infectious disease testing, has received U.S. Food and Drug Administration (FDA) De Novo authorization for the BIOFIRE® RP2.1 Panel. 

bioMérieux announces the expansion of the CE marking of its molecular biology ARGENE® SARS-CoV-2 diagnostic test to include saliva specimens.

17 November, 2020

Marcy l’Etoile, France – November 16, 2020 – bioMérieux, a world leader in the field of in vitro diagnostics, has announced the expansion of its ARGENE® range for the detection of SARS-CoV-2. As a complement to nasopharyngeal swab specimens, the singleplex SARS-CoV-2 R-GENE® real-time PCR test may now be used on saliva and oropharyngeal (throat) swab specimens for the detection of the virus that causes COVID-19. This development helps optimize laboratory workflows.

First-Half 2020 Results

02 September, 2020

Pioneering diagnostics